- Transaction increases profit potential of aducanumab for Biogen and provides near-term capital to Neurimmune
Biogen will make a one-time
“Biogen values our collaboration with Neurimmune, and this step is
aligned with our amended agreement from 2017,” said
“At Neurimmune, we are pleased with the continuous progress of our
long-term successful collaboration with Biogen,” said
About Aducanumab
Aducanumab (BIIB037) is an investigational
compound being developed for the treatment of Alzheimer’s disease.
Aducanumab is a human recombinant monoclonal antibody (mAb) derived from
a de-identified library of B cells collected from healthy elderly
subjects with no signs of cognitive impairment or cognitively impaired
elderly subjects with unusually slow cognitive decline using
Neurimmune’s technology platform called Reverse Translational Medicine
(RTM). Biogen licensed aducanumab from Neurimmune under a collaborative
development and license agreement.
Aducanumab is thought to target aggregated forms of beta amyloid including soluble oligomers and insoluble fibrils which can form into amyloid plaque in the brain of Alzheimer’s disease patients. Based on pre-clinical and Phase 1b data to date, treatment with aducanumab has been shown to reduce amyloid plaque levels.
In
As of
About Biogen
At Biogen, our mission is clear: we are
pioneers in neuroscience. Biogen discovers, develops, and delivers
worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases. One of the world’s first
global biotechnology companies, Biogen was founded in 1978 by
Biogen routinely posts information that may be important to investors on
its website at www.biogen.com.
To learn more, please visit www.biogen.com
and follow Biogen on social media – Twitter,
LinkedIn,
About Neurimmune
Neurimmune is a biopharmaceutical company
dedicated to the development of human-derived therapeutic antibodies for
the treatment and prevention of human diseases with a high unmet medical
need. Established in 2006, Neurimmune has rapidly grown into a leader in
the field of recombinant human monoclonal antibody therapeutics.
Neurimmune’s pipeline comprises high-potential drug candidates at both
clinical and advanced preclinical development stages. Aducanumab, an
investigational treatment for Alzheimer’s disease, partnered with
Biogen, is currently in phase 3 clinical trials. Rights in antibodies
BIIB054 for Parkinson’s disease and BIIB076 for Alzheimer’s disease were
acquired by Biogen. In 2016, Neurimmune partnered with TVM and Eli
Lilly’s Chorus unit to advance an antibody for the treatment of
amyotrophic lateral sclerosis. In 2017, Neurimmune entered into a
collaboration with
Biogen Safe Harbor Statement
This press release contains
forward-looking statements, including statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements relating to the anticipated benefits and
potential of Biogen’s collaboration agreement with Neurimmune; the
potential of Biogen’s commercial business and pipeline programs,
including aducanumab; and risks and uncertainties associated with drug
development and commercialization. These forward-looking statements may
be accompanied by words such as “aim,” “anticipate, “believe,” “could,”
“estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,”
“possible,” “will” and other words and terms of similar meaning. Drug
development and commercialization involve a high degree of risk, and
only a small number of research and development programs result in
commercialization of a product. Results in early stage clinical trials
may not be indicative of full results or results from later stage or
larger scale clinical trials and do not ensure regulatory approval. You
should not place undue reliance on these statements or the scientific
data presented.
These statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements,
including without limitation, uncertainty as to whether the anticipated
benefits and potential of Biogen’s collaboration agreement with
Neurimmune can be achieved; risks of unexpected costs or delays;
uncertainty of success in the development and potential
commercialization of aducanumab, which may be impacted by, among other
things, unexpected concerns that may arise from additional data or
analysis, the occurrence of adverse safety events, failure to obtain
regulatory approvals in certain jurisdictions, failure to protect and
enforce Biogen’s data, intellectual property and other proprietary
rights and uncertainties relating to intellectual property claims and
challenges; and third party collaboration risks. The foregoing sets
forth many, but not all, of the factors that could cause actual results
to differ from Biogen’s expectations in any forward-looking statement.
Investors should consider this cautionary statement, as well as the risk
factors identified in Biogen’s most recent annual or quarterly report
and in other reports Biogen has filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180501005335/en/
Source: Biogen
Neurimmune:
Fabian Buller, +41 44 755 4623
Chief
Business Officer
fabian.buller@neurimmune.com
or
Biogen:
MEDIA
CONTACT:
David Caouette, +1 617-679-4945
public.affairs@biogen.com
or
INVESTOR
CONTACT:
Matt Calistri, +1 781-464-2442
IR@biogen.com